FGFR1-3 inhibitor for FGFR+ tumors - Infigratinib BBIO - Infigratinib FGFR - ASCO 2020 - UC adjuvant Ph3 TiP BBIO - Infigratinib FGFR - ASCO 2020 - CCA Ph2 Javle 4591 BBIO - Infigratinib FGFR - ASCO 2020 - UC Ph1_2 Lyou 5038 BBIO - Infigratinib FGFR - ASCO GU 2020 - Ph3 adjuvant UC TiP BBIO - Infigratinib FGFR - ASCO GU 2020 - Ph1_2 UC efficacy vs hyperphos BBIO - Infigratinib FGFR - AACR 2019 - Preclinical fusion models BBIO - Infigratinib FGFR - ASCO 2019 - 1L CCA Ph3 TiP BBIO - Infigratinib FGFR - ASCO 2019 - Ph1_2 UC BBIO - Infigratinib FGFR - EMUC 2019 - Ph1_2 UC cfDNA BBIO - Infigratinib FGFR - ESMO 2019 - Ph2 UC cfDNA BBIO - Infigratinib FGFR - ESMO 2019 - 1L CCA Ph3 TiP BBIO - Infigratinib FGFR - WSAUA 2019 - Ph1_2 UC cfDNA BBIO - Infigratinib FGFR - ESMO 2018 - Ph2 CCA
